Study of Partially Hydrolyzed Formula with Synbiotics to Improve Skin Barrier in Infants at Risk of Allergy

What this Trial Is About

Researchers are evaluating the effects of a partially hydrolyzed formula with synbiotics on infants at risk of allergy, specifically aiming to stop early signs of the allergic march such as atopic dermatitis. This study focuses on infants up to 14 days old who have a family history of allergy and seeks to assess both the efficacy and safety of this formula in improving skin barrier function. Participants will be randomly assigned to one of three groups a partially hydrolyzed formula with synbiotics, an intact protein formula without synbiotics, or a breastfed reference group not applicable in France. The study compares these feeding methods to observe their impact on skin health and allergy development during the first year of life. Throughout the study, infants will be monitored from enrollment until 12 to 13 months of age. Evaluations include measuring skin water loss, skin hydration, severity of atopic dermatitis, immune responses, microbiome analysis, and growth parameters like weight, height, and head circumference. Safety assessments and allergic manifestations will also be tracked to better understand the effects of the formulas and breastfeeding on allergy risk.

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function